£3m Dementia Consortium launched to boost dementia drug discovery
After the first G8 summit on dementia research was held yesterday in the UK (http://dementiachallenge.dh.gov.uk/category/g8-dementia-summit/) , a new £3 million Dementia Consortium is being launched bringing together research experts from the charitable, academic and private sectors to expedite development of new drugs for dementia. The Dementia Consortium unites the charity Alzheimer’s Research UK with life science technology transfer experts MRC Technology and two pharmaceutical companies; Eisai and Lilly.
The Consortium will seek to end the long wait since the last dementia treatment by closing the gap between fundamental academic research and the pharmaceutical industry’s drug discovery programmes. The Dementia Consortium will provide funding, resources and expertise to both increase the number of, and capitalise upon, new drug targets emerging from across the academic sector that hold promise of bringing patient benefit.
The Dementia Consortium will fund leading academic dementia research…
View original post 719 more words